Revelation Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California. The company went IPO on 2020-10-08. Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
Mr. James Rolke es el Chief Executive Officer de Revelation Biosciences Inc, se unió a la empresa desde 2020.
¿Qué tal es el rendimiento del precio de la acción REVB?
El precio actual de REVB es de $1.22, ha aumentado un 2.52% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Revelation Biosciences Inc?
Revelation Biosciences Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Revelation Biosciences Inc?
La capitalización bursátil actual de Revelation Biosciences Inc es $4.5M
¿Es Revelation Biosciences Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 4 analistas han realizado calificaciones de análisis para Revelation Biosciences Inc, incluyendo 2 fuerte compra, 4 compra, 1 mantener, 0 venta, y 2 fuerte venta